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ABSTRACT 
 Cell foreign deoxyribonucleic acid (DNA) integration can occur non-naturally 
(transfections procedures) or naturally such as the integration of DNA from apoptotic 
bodies or by retrotransposition events. Viruses, the most abundant biological and 
diverse genetic entities on earth, capable of infecting the three major domains of life, 
can also become part of the genetic material of their host species and became 
endogenous viral elements (EVEs). These, could be derived from retrovirus, DNA or 
ribonucleic acid (RNA) viruses and there are several reports in animals and plant 
genomes. To date, just few EVEs related to the rabbit and hare genomes were 
reported in the European rabbit (Oryctolagus cuniculus) and European hare (Lepus 
europaeus), and rabbits have been used as a valuable animal model in research for 
the study of human diseases as they immune response to antigens is excellent and 
the well studied physiology of cells, sera, tissues and organs is more similar to 
humans than of mice and rats. 
 Hepatitis C virus (HCV) was discovered in 1989 and is the major causative 
agent of acute and chronic liver disease that can lead to hepatocellular carcinoma 
and death. HCV belongs to the Flaviviridæ family, genus Hepacivirus, and contains a 
single-strand positive-sense RNA genome. Only several years after HCV discovey 
some aspects of its life cycle were revealed due to a lack of an efficient cell culture 
system. HCV exhibits high genetic diversity and nowadays comprise 7 genotypes 
and 67 subtypes that are globally distributed. Moreover, HCV routes of transmission 
are strongly linked to the HCV high prevalence globally and are also related its high 
genetic diversity of the virus. The diagnosis of HCV infection is based on the 
presence of anti-HCV antibodies using enzyme immunoassays or the virus detection 
by conventional polymerase chain reaction (PCR) or real-time PCR. Nowadays, HCV 
treatment is based in combinations of direct-acting antivirals (DAAs) drugs 
(Sofosbuvir, Simeprevir and Daclatasvir) plus/not plus interferon-! and/or ribavirin. 
The human hepatoma cell line Huh-7 and clonal derivatives seems to be the most 
permissive cell lines for efficient RNA replication, resulted from manipulated genomic 
HCV strains, in vitro. However, other HCV-permissive cells like human non-liver 
origin, human liver-derived cells, and non-human cells have been described. Primary 
human hepatocytes (PHH) provide the closest in vitro model for the natural host cell 
of HCV and there are several studies reporting there use for wild type HCV isolates. 
XXXII 
 
Although, as primary cells they rapidly lose their differentiation status influencing their 
use in HCV research. Small animal models with numerous experimental approaches 
have been taken to recapitulate parts of the virus life cycle and/or aspects of viral 
pathogenesis, but currently, chimpanzees remain the only model available for HCV 
research. To date the HCV origin remains unclear and HCV life cycle and 
pathogenesis are not enlightened processes. There have been recent descriptions 
on several studies reporting homologs of HCV detected in animals that could be a 
valuable contribute in these fields. Partially, our investigation also focused in the 
search for significant natural viruses reservoirs associated to animal or human 
diseases. Within this search we were led to hypothesize about the role of the 
European rabbit (O. cuniculus) and European hare (L. europaeus) as natural 
reservoirs of Flaviviridae or more precisely precursors of HCV-like viruses in this 
thesis. 
 Therefore, samples such as liver homogenates, body fluids, white blood cells, 
serum, liver homogenates inoculated in Mardin-Darby Bovine Kidney (MDBK) and/or 
bovine testicle (BT) cell cultures or DNA inoculated in MDBK cells, from wild and/or 
domestic European rabbits and/or from European hare were evaluated using 
different methods such as for PCR, reverse transcriptase-PCR (RT-PCR), mass 
spectrometry, immunofluorescence assay (IFA) and immunogold electron 
microscopy (IEM) assays. Endogenous HCV homolog fragments coding for HCV 
core, envelope glycoprotein’s E1 and E2, protease NS2-3, serine protease NS3, 
NS4A, NS5A and NS5B specific proteins were detected in the tested animals 
genomes, showing their capacity to internalize and autoreplicate in MDBK and/or BT 
cell cultures. Moreover, when MDBK cells were inoculated with the rabbits or hare 
total DNA samples it was shown that HCV-like viruses are produced and that they 
are closely related to the HCV-1a and/or HCV-1b genotypes. 
 Additionally, preliminary work using synthetic fragments homologs to HCV and 
HCV wild type sera (HCV-1a, HCV-2c and HCV uncharacterized) samples were also 
inoculated in MDBK and/or BT cell cultures and evaluated by similar methods as of 
the animal samples. The results obtained suggests for the internalization and 
replication of the tested samples in the used bovine cell cultures.  
 The data presented in this thesis could contribute to understand the HCV 
origin and for a better understanding of the virus life cycle and pathogenesis, as well 
as contribute to the discovery of new antivirals and perhaps a vaccine production. 
XXXIII 
 
Resumo 
 O ácido desoxirribonucleico (ADN) pode ser inserido em células hospedeiras 
por via artificial (transfecção) ou naturalmente, por exemplo pela integração de ADN 
proveniente de corpos apoptóticos ou por eventos de retrotransposição. Os vírus são 
as entidades biológicas mais abundantes e geneticamente diferentes existentes na 
terra, sendo capazes de infetar os três principais domínios da vida. Estes podem 
ainda integrar o material genético das espécies hospedeiras normalmente 
referenciados como elementos virais endógenos (EVEs). Os EVEs podem ser 
derivados de retrovírus, vírus de ADN ou de ácido ribonucleico (ARN) e já foram 
descritos em genomas de plantas e de animais.  
 Até ao presente, muito poucas descrições têm associado os EVEs ao genoma 
do coelho e da lebre, havendo unicamente referências nas espécies de coelho 
Europeu (Oryctolagus cuniculus) e lebre Europeia (Lepus europaeus). O coelho tem 
sido também utilizado como espécie animal modelo relevante em investigação ligada 
a doenças humanas, uma vez que a sua resposta imunitária aos antigénios é 
excelente e, também porque a fisiologia das células, soros, tecidos e órgãos têm 
sido bem estudadas e assemelham-se em muitos aspetos aos seres humanos 
comparativamente aos ratos e ratazanas. 
 O vírus da hepatite C (VHC), descoberto em 1989,é o principal agente 
etiológico de doença hepática aguda e crónica que pode desencadear o 
desenvolvimento do carcinoma hepatocelular e morte. O VHC pertence à família 
Flaviviridae, género Hepacivirus, e possui um genoma de ARN de cadeia simples e 
polaridade positiva. Só apenas alguns anos após a sua descoberta foi possível 
desvendar alguns aspetos do seu ciclo de vida, principalmente porque a 
investigação na área do VHC tem sido dificultada pela escassez de sistemas de 
cultura de células eficientes. O VHC apresenta uma elevada variabilidade e 
consequente diversidade genética, e sabe-se que hoje engloba 7 genótipos e 67 
subtipos que estão globalmente distribuídos. A sua transmissão está 
intrinsecamente associada à sua elevada prevalência a nível mundial e também 
relacionada à grande diversidade genética apresentada pelo vírus. O diagnóstico da 
infeção pelo VHC baseia-se na deteção de anticorpos anti-VHC através da utilização 
de ensaios imunoenzimáticos ou deteção do vírus utilizando o método convencional 
da reação em cadeia da polimerase (PCR) ou PCR em tempo real. O tratamento da 
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Hepatite C é baseado na utilização de combinações de drogas (Sofosbuvir, 
Simeprevir e Daclatasvir) antivirais de ação direta (DAAs) suplementadas ou não 
com interferão-! e/ou ribavirina. A cultura de células de linha do hepatoma humano 
Huh-7 e seus clones derivados têm-se apresentado como o melhor sistema de 
células permissivas à replicação eficiente do ARN, obtido de estirpes do VHC que 
foram geneticamente manipuladas, in vitro. No entanto, foram também descritos 
outros tipos de células permissivas ao VHC, tais como, células sem origem no fígado 
humano, outras derivadas do fígado humano e células sem origem humana. Os 
hepatócitos primários humanos (HPH) apresentam-se como o modelo in vitro mais 
próximo da célula hospedeira natural do VHC, e há vários estudos que descrevem a 
sua utilização para a multiplicação dos isolados de campo do vírus. No entanto, 
estas células primárias perdem muito rapidamente a sua capacidade de proliferação 
o que influencia a sua utilização na investigação do VHC. Já foram utilizados 
diversos modelos animais de pequeno porte para diferentes abordagens 
experimentais com o VHC, nos quais se conseguiram reproduzir partes do ciclo de 
vida do vírus e/ou aspetos da patogénese viral. No entanto, atualmente, os 
chimpanzés continuam a ser o único modelo disponível para a investigação do VHC. 
Até ao presente desconhece-se a origem do VHC e há fases e processos do seu 
ciclo de vida e patogénese por esclarecer. Alguns estudos mais recentes têm 
descrito a deteção de vírus homólogos ao VHC em diferentes espécies animais, 
podendo estes constituir um valioso contributo para esclarecimento destas áreas. 
Em certa medida, a nossa linha de investigação também tem como foco a procura 
de reservatórios naturais de vírus importantes associados a doenças animais ou 
humanas. A investigação apresentada nesta tese teve como base considerar a 
hipótese de qual poderia ser o papel do coelho Europeu (O. cuniculus) e da lebre 
Europeia (L. europaeus) enquanto reservatórios naturais de vírus da família 
Flaviviridae e mais especificamente, como precursores de vírus semelhantes ao 
VHC. 
 Para atingir os objetivos propostos, foram analisadas diversas amostras de 
coelho e de lebre, tais como homogeneizados de fígado, fluidos corporais, 
leucócitos, soro, homogeneizados de fígado inoculados em células epiteliais de rim 
de bovino (MDBK) e/ou testículo de bovino (BT), ou ADN total das duas espécies 
animais em estudo inoculados em células MDBK, utilizando diferentes métodos de 
diagnóstico e de investigação tais como, PCR, PCR via transcriptase reversa (RT-
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PCR), espectrometria de massa, ensaio de imunofluorescência (IFA) e de 
imunomicroscopia electrónica (IEM). Foram detetados nos genomas dos animais 
testados, fragmentos endógenos homólogos ao VHC que codificam para proteínas 
do VHC, mais especificamente para as proteínas do “core”, glicoproteínas do 
invólucro E1 e E2, NS2-3 protease, NS3 serina-protease, NS4A, NS5A e NS5B, as 
quais demonstraram a capacidade de internalização e autoreplicação destes em 
células MDBK e/ou BT. Quando as células MDBK foram inoculadas com as 
amostras de ADN total do coelho ou lebre foi demonstrada a produção de partículas 
víricas semelhantes às do VHC as quais são muito próximas geneticamente aos 
genótipos VHC-1a e/ou VHC-1b. 
 Adicionalmente, foram realizados trabalhos de investigação utilizando 
amostras de fragmentos sintéticos homólogos ao VHC (regiões do “core”, E2 e 
NS4B) e de soros contendo estirpes de campo (VHC-1a, VHC-2c e VHC não-
caracterizados) inoculadas em células MDBK e/ou BT, igualmente avaliadas por 
métodos de diagnóstico e de investigação semelhantes aos utilizados nos estudos 
anteriores. Os resultados preliminares obtidos sugerem a internalização e a 
replicação das amostras testadas nas culturas de células de espécie bovina 
utilizadas neste projeto. 
 Os resultados apresentados nesta tese poderão contribuir para o 
esclarecimento da origem do VHC e para um melhor esclarecimento do ciclo de vida 
e patogénese do vírus, assim como contribuir para a descoberta de novos antivirais 
e talvez na produção de uma vacina. 
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CELL FOREIGN DNA INTEGRATION, ENDOGENOUS VIRAL ELEMENTS, 
ENDOGENOUS VIRAL ELEMENTS INTEGRATED IN EUKARYOTIC GENOMES 
AND POSITIVE RNA VIRUSES 
 
1. 1 - Cell Foreign DNA Integration 
 Foreign deoxyribonucleic acid (DNA) integration is one of the most intriguing 
cellular processes in molecular biology. For example, the development of several 
transfection procedures enable the DNA to enter into the cytoplasm, however its 
passage into the nucleus is mainly mediated by the cells machinery (1, 2) and after 
nucleus entry, the foreign DNA is large and rapidly degraded or diluted among 
subsequent cell divisions (3). Thus, under certain conditions, molecules containing 
an origin of replication such as a derived from viruses could persist for long periods 
as extrachromosomally replicating episomes, for example as expression of viral 
tumor antigens or in association with the nuclear matrix (4). In fact, foreign DNA 
integration process is not limited to laboratory transfections, integrative 
recombination studies or gene therapy studies for instance, as many natural cellular 
processes, such as the integration of DNA from apoptotic bodies (5) or 
retrotransposition events, give rise to de novo integration of DNA (6). Indeed, DNA 
integration may be seen as an ongoing natural process, which can be applied to 
artificially introduce modifications to cells in a genetic content. Moreover, viral DNA 
integration events appear to be identical in nature to any type of foreign DNA 
integration (4). Furthermore, in various natural and experimental scenarios, 
mammalian genomes become the targets for foreign DNA insertions, and so several 
DNA- and ribonucleic acid (RNA)-containing viruses are capable of integrating their 
genomes into the genomes of their host cells (7, 8).  
 
1.2 - Endogenous Viral Elements 
 Viruses are the most abundant biological and diverse genetic entities on earth. 
They are environmentally ubiquitous and are capable of infecting Eukaryota, Bacteria 
and Archaea organisms as well as other viruses (9). Due to the infectious properties 
of viruses, which enable them to spread horizontally between individuals and across 
species, many viruses can also become part of the genetic material of their host 
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species, a process that is called endogenization (10). Moreover, viral insertions that 
result from the chromosomal integration of viral (DNA ) (or DNA copies of viral RNA 
in the host germ cells, which allows for vertical transmission and potential fixation in 
the host population, are called endogenous viral elements (EVEs) (11). EVEs were 
so far thought to be limited to retrovirus, endogenous retroviruses, but in a recent 
study (10) it was shown that EVEs could be derived from DNA (single or double 
strand) or RNA (positive or negative single strand and double strand) viruses too. 
 
1.3 - Endogenous Viral Elements integrated in Eukaryotic Genomes 
 Most RNA virus EVEs identified to date derives from RNA viruses with 
negative-sense genomes or from RNA viruses that lack DNA intermediates (12-14). 
EVEs derived from flavivirus-related RNA viruses were first described in insects in 
2004 (15). This description involves a gene sequence of an RNA virus that replicate 
using an RNA-dependent RNA polymerase integrated into the Aedes spp. 
mosquitoes genome (15). Recently, Katzourakis and Gifford described the presence 
of EVEs in animal genomes, including viruses derived from single-strand positive-
sense RNA (ssRNA+) viruses, which has revolutionized the understanding of the 
processes and time-scale of viral evolution (11). More recently, EVEs that share a 
sequence similarity to ssRNA+ viruses of plants integrated into the genomes of 
insects have also been reported (16). However, EVEs derived from ssRNA+ viruses 
appear in extremely low copy numbers in the genomes; one genomic copy in the 
case of the Reoviridae, five in the case of the Flaviviridae and a small number in 
Potato virus Y were previously described (17). Moreover, EVEs from ssRNA+ viruses 
in honeybees were also described (18). More recently, a study that included EVEs 
related to ssRNA+ viruses also showed several EVEs related to negative ssRNA 
viruses, single and double strand DNA viruses, ssRNA-reverse transcriptase viruses 
and double strand-DNA-reverse transcriptase viruses in several Eukaryota genomes 
(10). 
 
1.4 - Positive RNA Viruses 
 Positive RNA viruses are characterized by an ssRNA+ genome, which, upon 
virus entry and uncoating, functions as mRNAs and thus can be directly translated 
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into proteins by host cell machinery (19).Therefore, the genomic RNA could work as 
template for viral RNA replication. Following translation and processing of the viral 
polyprotein(s) and viral non-structural (NS) proteins, the viral RNA and host factors 
form membrane-associated replication complexes that carry out viral RNA synthesis 
(20, 21). The resultant progeny positive RNA strands can either initiate a new 
translation cycle or be packaged into virions that are subsequently released to infect 
naïve cells (20). Moreover, host factors participate in almost all or probably in all 
steps of ssRNA+ virus infection, including entry, viral gene expression, virion 
assembly and release (20). Furthermore, host factors are targeted by ssRNA+ 
viruses to modulate host gene expression and defenses (20). 
 
EUROPEAN RABBIT AND EUROPEAN HARE 
 
1.5 - The European Rabbit (Oryctolagus cuniculus) 
 The European rabbit (Oryctolagus cuniculus), wild and domestic, are small 
mammals that belong to the Leporidae family within the order Lagomorpha. 
Oryctolagus cuniculus (O. cuniculus) which origin remains to the discovery of an 
oldest known rabbit fossil (6.5 million years) in the Iberian Peninsula (Andalusia, 
Spain) is the sole extant representative of the genus Oryctolagus (22). Two 
morphologically differentiated subspecies have been distinguished in 1914, the O. 
cuniculus algirus and O. cuniculus cuniculus respectively, and recently it was shown 
that they diverged ~1.8 million years (23, 24). Geographically, O. cuniculus algirus 
are located in the southwest and O. cuniculus cuniculus in the northeast of the 
Iberian Peninsula. O. cuniculus cuniculus expanded its range to the North towards 
France after the last glacial maximum (25), and still remains there. The rabbit 
distribution had a major impact when humans, during the Middle Ages, started 
transporting them to many other geographical areas (26) being found worldwide 
nowadays (e.g., Algeria; France; Gibraltar; Morocco; Portugal; Spain, Albania; 
Argentina; Australia; Austria; Belgium; Bulgaria; Chile; Croatia; Czech Republic; 
Denmark; Falkland Islands (Malvinas); Germany; Greece; Hungary; Ireland; Italy; 
Luxembourg; Namibia; Netherlands; New Zealand; Norway; Poland; Romania; 
Russian Federation; Slovakia; Slovenia; South Africa; Sweden; Switzerland; United 
Kingdom and United States). 
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 On one hand, O. cuniculus is considered a pest in many countries and islands 
outside its natural range on the Iberian Peninsula, especially in Australia, South 
America and other European countries (27-33). On the other hand, during the 20th 
century, the number of rabbits on the Iberian Peninsula has declined >90% mainly 
because of viral diseases named myxomatosis, caused by a myxoma virus infection, 
and viral haemorrhagic disease; caused by the rabbit haemorrhagic disease virus 
and since 2011 the mortality rates are higher in Spain and Portugal due to the 
identified new variant of rabbit haemorrhagic disease virus that strongly affects 
domestic and wild rabbits populations (34, 35). Indeed, the European rabbit is 
currently classified in the International Union for Conservation of Nature (IUCN) in the 
red list of threatened species as near threatened (36). 
 The rabbits are valuable animal models in biomedical and fundamental 
research because they have many hereditary diseases (e.g. aortic arteriosclerosis, 
hypertension, hypertrophic cardiomyopathy and osteoporosis) common to humans 
and they have been commonly used in studies of toxicology, in vitro fertilization, 
embryology and organogenesis (37) as will be better exposed below. 
 
1.6 - The European Hare (Lepus europaeus) 
 The European hare (Lepus europaeus), also known as brown hare, belong to 
the genus Lepus (order Lagomorpha, family Leporidae). The current Eurasian 
distribution of Lepus europaeus (L. europaeus) extends from the northern provinces 
of Spain, to introduced populations in the United Kingdom and southern regions of 
Scandinavia, south to northern portions of the Middle East, and has naturally 
expanded in the east to sections of Siberia (38). This species has been introduced as 
a game species extensively in several countries across the world [e.g., Argentina, 
Australia, Barbados, Brazil, Canada, Chile, Falkland Islands, New Zealand (North 
and South Island), Réunion, the United Kingdom and the United States] (38). The 
numbers of European hares have declined throughout Europe, with evidence of 
population decline beginning in the 1960s in association with the intensification of 
agricultural practices (39). In the last decades, a progressive decline in the hare 
population across Europe has also been associated to the occurrence of the 
European brown hare syndrome, a highly contagious disease caused by the 
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European brown hare syndrome virus, which nowadays is considered endemic in all 
European countries (40-42). Several countries have placed L. europaeus on their red 
list as near threatened or threatened (43) however the IUCN had placed it in the red 
list of threatened species as least concern (44). 
 
1.7 - The European Rabbit and Hare Genomes and EVEs Integration 
 Comparative cytogenetic tools revealed that within the Leporidae family, which 
includes 56±60 recognized species depending on classifications, the chromosome 
numbers vary from 2n = 38 to 52 (45). Furthermore, when using available banded 
karyotypes for seven of the eleven Leporidae genera, a presumed ancestral 
karyotype with 2n = 48 chromosomes conserved with those of the European hare 
can be reconstituted (46). Moreover, it was shown that rabbit karyotype (2n = 44) 
differs from that of the European hare (2n = 48) by the presence of two centric 
fusions and that within Leporidae, karyotypes have either retained the presumed 
lepus-like ancestral state or have undergone various chromosomal rearrangements 
leading to chromosome patterns unique to each lineage (45, 47). Since the 1980s 
until today, several genetic polymorphisms in immunoglobulins, mitochondrial DNA 
and major histocompatibility complex class II genes, at a genetic variability level, 
have been described for rabbit and hare (48-54). 
 To date just few EVEs related to the rabbit and hare genomes were reported, 
and only to the European rabbit (O. cuniculus) and European hare (Lepus 
europaeus) genomes. The EVEs, of lentivirus origin, related to rabbit was first 
reported by Katzourakis et al, in 2007, and was named rabbit endogenous lentivirus 
type K (RELIK) (55). Moreover, it was also reported that these viruses integration 
were more than 7 million years old showing the first evidence for an ancient origin of 
the lentiviruses, however, later it was shown that these viruses diverged some 12 
million years ago (56). Furthermore, the presence of the endogenous RELIK was 
newly reported in the rabbit genome in 2012 (57). In addition, a human retrovirus 5 
was described as endogenous in the European rabbit genome (58). For the 
European hare, the identification of a RELIK orthologue in its genome with a 
minimum age of 12 million years for the lagomorph lentiviruses was described (59). 
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1.8 - Rabbits as Animal Models for the Study of Diseases 
1.8.1 - Human Diseases 
 The biomedical research, basic science and applied research, is a huge effort 
that answers to medical questions, requiring the input and participation of many 
individuals with many different backgrounds and skills, such as, from life, 
biochemistry and physical sciences, among others. Moreover, they involve the 
investigation of the biological processes and the causes of diseases through careful 
experimentation, which involves observation, laboratory work, analysis and testing. 
The use of animals in laboratory experiments, following all ethical statements, 
presents an important contribute in this field, which can lead to the development of 
new preventions, therapies and cures for human and veterinary health. 
 The rabbit is a valuable animal model and research tool. For example, its 
immune response to antigens is excellent (45). The physiology of cells, sera, tissues 
and organs has been well studied and in several aspects is more similar to humans 
than mice and rats (45). They have small size, and are appropriate to collect 
adequate amounts of blood, milk or tissue samples for experiments or to be used for 
surgical experiments when compared with mice and rats, and the environment in 
which they are breed can be easily assayed (45). Firstly, rabbits were used for the 
production of antibodies and non-clinical safety studies for testing compounds, such 
as dermal tolerance test, pyrogen test, reproduction toxicity studies or ocular 
tolerance tests (60). Since 1980 the rabbit was introduced to function as an animal 
model for human diseases, using naturally mutant animals, genetic manipulated or 
through selective breeding (60). For example, in human hypercholesterolemia 
studies (translational medicine) it was shown that rabbits lipoprotein metabolism 
resembles of humans, when spontaneous hypercholesterolemic rabbits were used 
(61). Recently, a number of transgenic rabbits have been developed and contributed 
to the study of human cardiovascular diseases (62). Furthermore, rabbit models have 
been widely used for various purposes linked to human diseases studies as shown in 
Table 1. 
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Table1. Example of rabbit models applied to human diseases studies, adapted from 
(60). 
Human diseases Rabbit models 
Lipid metabolism disorder  
Hypercholesterolemia  WHHL* rabbit, WHHLMI* rabbit, cholesterol/ western 
diet-fed rabbit 
Hyperlipidemia  SMHL* rabbit 
Postprandial 
hypertriglyceridemia  
PHT* rabbit 
Metabolic syndrome  WHHLMI rabbit, SMHL rabbit, PHT rabbit 
Cardiovascular diseases  
Atherosclerosis WHHL rabbit, WHHLMI rabbit, cholesterol/ western 
diet-fed ordinary rabbit 
Coronary atherosclerosis WHHL rabbit, WHHLMI rabbit, cholesterol/ western 
diet-fed ordinary rabbits 
Cerebral atherosclerosis  WHHL rabbit, WHHLMI rabbit 
Myocardial infarction  WHHLMI rabbit 
Cardiac function  WHHLMI rabbit, ordinary normal rabbits 
Prolonged QT syndrome  Transgenic rabbits 
Other diseases  
Xanthoma WHHL rabbit, WHHLMI rabbit 
Infectious diseases New Zealand white rabbits, transgenic rabbits 
(Tuberculosis, Papillomavirus, Prion diseases) 
Inflammatory response Transgenic rabbits 
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Orthopedic surgery Ordinary normal rabbits (Osteonecrosis, meniscal 
repair, autologous osteochondral transplantation, 
osteochondral defects) 
Cardiovascular surgery Ordinary normal rabbits (Spinal cord ischemia due to 
back-bleeding, dysfunction of aortic valve) 
Transplantable Neoplasms Ordinary normal rabbits (VX2 lung cancer, Kato 
sarcoma, Kondrateva osteogenic sarcoma, Brown-
Pearce Carcinoma) 
Keratopathy WHHL rabbit, WHHLMI rabbit 
Overactive bladder WHHLMI rabbit 
Hypacusia WHHL rabbit 
Chronic pancreatitis WHHL rabbit 
*WHHL-Watanabe heritable hyperlipidemic; WHHLMI-Watanabe heritable 
hyperlipidemic myocardial infarction-prone; SMHL-6W7KRPDV¶PL[HGhyperlipidemic; 
PHT-Postprandial hypertriglyceridemic. 
 
1.8.2 - Infectious Diseases, RNA Viruses 
 During the 1980s and early 1990s several reports linked to RNA and DNA 
viruses, bacterial and fungal human infectious diseases using the rabbit as animal 
model were described (63). For example, the use of New Zealand White and the 
French Lop rabbits for studying the pathogenesis and immunology of rotaviruses 
infections were reported. In these studies it was demonstrated that the rabbit is 
susceptible to endogenous rotavirus strains that caused a disease that resembles the 
human disease epizootiologically and clinically (63-65). A non-respiratory animal 
model (New Zealand White rabbits) was developed to study the role of cellular 
immunity to parainfluenza virus type 3 infections and a T-cell response was 
developed, associated to the gut lymphoid tissue and in the bowel wall of PI-3 
infected rabbits (66). Studies involving rabbits infected with human immunodeficiency 
virus (HIV) -1 were also described in this decade. One study showed that rabbits 
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infected with supernatant of H9 cells infected with HIV-1 produced detectable 
antibodies 2 weeks post infection and these animals remained seropositive for one 
year (67). Recently, a study designed to show whether molecular mechanisms are 
involved in the pathogenesis of fulminant hepatic failure in experimentally infected 
rabbits (as animal model) with rabbit hemorrhagic disease virus was described. 
These results support the rabbit usefulness, as animal model, in the investigation of 
potential novel therapeutically modalities aimed at neutralizing reactive oxygen 
species and hepatocyte growth inhibitors or enhancing hepatocyte responsiveness to 
mitogens (68). More recently, Cheng and colleagues (69), following the identification 
of hepatitis E virus from rabbits (70), accessed the possibility of using rabbits as a 
non- human primate animal model for hepatitis E virus infection and vaccine 
evaluation (69). They have concluded that the rabbits may serve as an alternative 
model for hepatitis E virus infection and vaccine evaluation of selected strains, with 
the appropriate viral dosages and use of the intravenous route for virus inoculation 
(69). 
 
HEPATITIS C VIRUS 
 
1.9 - Disease 
 Hepatitis C virus (HCV), a positive RNA virus with a +ssRNA genome is the 
cause of a contagious liver disease that is characterized by two phases, an acute 
and chronic phase. The acute hepatitis C infection involves a short-term illness that 
develops within the first six months after a person has been exposed to the HCV 
virus. The acute hepatitis C infections can lead to chronic hepatitis. Chronic hepatitis 
C infection involves illness that is long-term and happens when the HCV virus is not 
cleared from the infected person. The infection may last for the duration of the 
person's lifetime, leading to serious complications in the liver, such as cirrhosis or 
hepatocellular carcinoma (HCC), or even result in death of the host (World Health 
Organization). 
 
1.10 - Discovery 
 Throughout the 1970s and early1980s clinicians and epidemiologists found 
that when a substantial number of patients were screened for hepatitis viruses they 
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were not related with hepatitis A or hepatitis B viruses. Consequently, a new form of 
hepatitis was achieved, the non-A non-B hepatitis (NANBH). At this time chronic 
NANBH associated with blood transfusion and therapy with plasma-derived blood 
products was described (71-75). However, this new clinical entity remained unclear. 
Later, in 1989, Choo et al. (Chiron Corporation) addressing molecular biological 
methods isolated a complementary DNA clone (5-1-1) from a blood-borne non-A, 
non-B viral hepatitis genome that was shown to be derived from a new ³flavi-like´ 
YLUXV DQG ZDV WHUPHG WKH ³KHSDWLWLV & YLUXV³ (76). For this, large volumes of 
chimpanzee sera with high infectious titers of NANBH were extracted for RNA and 
DNA isolation. From RNA, complementary DNA (cDNA) was performed and then 
inserted into a bacteriophage expression vector lambda gt 11, resulting in a random-
primed cDNA library with millions of clones (76). Then, using a blind 
immunoscreening approach, the cDNA library was screened using plasma from 
NANBH infected patients which resulted in the isolation of a positive clone called 5-1-
1 with ~10,000 nucleotides derived from an RNA molecule found only in NANBH-
infected samples. The southern blot analysis indicated that the clone was not a host 
gene derived from the chimpanzee or human genome and that it only bounded to 
antibodies in NANBH infected patients (76). A larger clone from the same library, 
clone 81, was also investigated and confirmed the potential viral origin of clone 5-1-1 
(76)7KLVZRUNOHDGHGWRWKHGLVFRYHU\RIWKH³KHSDWLWLV&YLUXV´ 
 
1.11 - Taxonomy 
1.11.1 - Genus Classification 
 The Flaviviridae family is classified by the International Committee on 
Taxonomy of Viruses (ICTV), http://ictvdb.bio-mirror.cn/Ictv/fs_flavi.htm) as a 
composite of tree genus of assigned viruses, the Flavivirus, Pestivirus and 
Hepacivirus, with the HCV (a virus that infect humans) considered the only member 
of the Hepacivirus genus. However, recently, the Flaviviridae family was for the first 
time described as including four genera, Flavivirus, Pestivirus, Hepacivirus, including 
the GBV- B viruses (77) and others viruses that are able to infect animals, and 
Pegivirus (78) (Figure 1.1), due to the description of HCV-like viruses, previously 
termed Hepacivirus, that were able to infect dogs, horses, bats and rodents (79-82) 
and viruses that infect bats and rodents homologous to the genus Pegivirus (81, 82). 
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Figure 1.1. Flaviviridae division into four genera. Phylogenetic tree of the family 
Flaviviridae showing its primary division into four genera (78). 
 
1.11.2 - Genotypes and Subtypes Classification 
 The first nearly complete genome identification of HCV occurs in 1989 when 
the virus was discovered and named HCV for the first time. Soon after, genetic 
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diversity of the virus was demonstrated when isolates from different individuals or 
countries were screened. Later, in 2005, this variation leaded to genotypes and 
subtypes assignment in a consensus classification and nomenclature system (77). 
Moreover, for genotype and subtype assignments four rules were established: one or 
more complete coding region sequence(s) should be determined; at least three 
epidemiologically unrelated isolates; a phylogenetic group distinct from previously 
described sequences; and exclusion of intergenotypic or intersubtypic recombination, 
whether the components were classified or not (77, 83). Furthermore, updates and 
changes of the rules for genotype/subtype assignments related to subtype names; 
provisional genotypes and subtypes; recombinant and other forms; and proposals for 
new genotype/subtype assignments were recently proposed (83).  
 In the last years the molecular biology technology approaches, such as 
polymerase chain reaction (PCR) and sequencing methods (such as dideoxy 
sequencing and pyrosequencing), contributed to an important increase of the vastly 
encountered HCV genetic variation in disease and treatment approaches. A large 
number of sequences became available in sequence databases (such as, National 
Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/), Los 
Alamos HCV Sequence Database (http://hcv.lanl.gov/content/index), "#$%&'()! *+,!
-(.(/(0' (euHCVdb) (https://euhcvdb.ibcp.fr/euHCVdb/), Hepatitis Virus Database 
(http://s2as02.genes.nig.ac.jp/)), and several of them contributed for the new 
described expanded classification of HCV into 7 genotypes and 67 subtypes (83) 
(Figure 1.2). Additionally, it was also shown that HCV strains belonging to different 
genotypes differ at 30 to 35% of nucleotide sites and strains that belong to the same 
subtype differ at <15% of nucleotide sites with all genotypes having a similar 
replication cycle in the host and capable of causing asymptomatic and chronic 
infections (83)  
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Figure 1.2. Phylogenetic tree of 129 representative complete coding region 
sequences. Up to two representatives of each confirmed genotype/subtype were 
aligned (together with a third extreme variant of subtypes 4g and 6e) and a neighbor 
joining tree constructed using maximum composite likelihood nucleotide distances 
between coding regions using molecular evolutionary genetics analysis 5 (MEGA5). 
Sequences were chosen to illustrate the maximum diversity within a subtype. Types 
are labeled by accession number and subtype (*unassigned subtype). For genotypes 
1, 2, 3, 4, and 6, the lowest common branch shared by all subtypes and supported by 
RIERRWVWUDSUHSOLFDWHVQ LVLQGLFDWHGE\Ɣ(83). 
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1.12 - Structure and Genome Organization 
 HCV are small (55-65nm in size) enveloped viruses and the viral particle 
consists of a core of genetic material (RNA), surrounded by an icosahedric protective 
shell of protein, and further encased in a lipid envelope of cellular origin (84) (Figure 
1.3A). HCV contains a ssRNA+ genome of ~9,600 nucleotides and is composed of a 
ƍ XQWUDQVODWHG UHJLRQ (UTR), a long open reading frame (ORF) encoding a 
polyprotein precursor of ׽DPLQRDFLGVDQGDƍ875(85, 86) (Figure 1.3B). The 
5`and 3`UTR regions are highly conserved RNA structures important for genome 
replication and protein translation. The polyprotein is composed by several proteins 
that are necessary for viral particle attachment and entry into the host cells, including 
structural (FRUHDQGHQYHORSH(JO\FRSURWHLQ¶V(DQG(and NS (p7, NS2, NS3, 
NS4A, NS4B, NS5A and NS5B) proteins (86-88) (Figure 1.3B).!
Figure 1.3. Schematic representation of the HCV viral particle and genome 
structures, adapted from (89, 90). (A) HCV viral particle; the HCV core protein 
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interacts with viral genomic RNA to form the nucleocapsid. Two membrane-
associated envelope glycoproteins, E1 and E2 are embedded in a lipid envelope 
which is derived from the host. (B) The single open reading frame encode a 
polyprotein with 10 viral proteins that are divided into the structural (core, E1 and E2; 
in blue) and non-structural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B; in green) 
proteins. The small peptide p7 is currently unassigned into either category (yellow). 
The open reading frame is flanked by 5`UTR and 3`UTR regions that are involved in 
both replication and translation. Following translation, the viral polyprotein is 
processed by two cellular protease activities, signal peptidase (SP; black arrow) and 
signal peptide peptidase (SPP; gray arrow), to yield core, E1, E2, and p7. The NS2-
NS3 autoprotease (orange arrowhead) and the NS3 serine protease as a complex 
with NS4A (purple arrowhead), generate mature proteins from the NS2-NS5B region. 
Core, E1, and E2 provide physical components of the virion. The p7 and NS2 are 
essential for virus assembly (red stars). NS4A and NS5B (black circles) are critical for 
viral RNA replication. NS3, NS4B, and NS5A have dual functions in viral RNA 
replication and particle production (blue diamonds). 
 
1.13 - Life Cycle 
 HCV was discovered in 1989 (76), but only several years latter it was possible 
to highlight some aspects of its life cycle, mainly because HCV research has been 
hampered by the lack of efficient cell culture systems. However, the generation of 
subgenomic HCV replicons (91), the HCV pseudoparticle approach (92) and 
infectious HCV culture systems (93-95) were crucial developments that assisted to 
understand and obtain a more complete view of HCV life cycle. HCV infects and 
replicates in liver hepatocytes of infected patients and so cell culture systems 
approaching the hepatoma cells lines, such as Huh-7 cell line (96, 97) seemed to be 
the most suitable to understand the virus life cycle, however, this cell line lacks some 
features of the hepatocytes (98). Indeed, nowadays just hypothetical models for the 
virus life cycle are suggested and so HCV life cycle stills an active research area. 
 
1.13.1 - Entry 
 HCV entry is a complex and multi-step process requiring a set of entry 
proteins (Figure 1.4). During a primary infection, HCV particles are transported by the 
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blood stream, cross the fenestrated endothelium of the liver sinusoids and in the 
space of Disse, the virions have direct contact with the basolateral surface of 
hepatocytes allowing them to interact with factors and receptors present in this 
surface (99). 
 Initial attachment of HCV virions into hepatocytes, depending on virion density, 
could be mediated by the heparan sulfate proteoglycan syndecan-1 or syndecan-4 
(100, 101) or by the scavenger receptor class B type I (SRB1) (102, 103). However, 
more recent data suggest that apolipoprotein E (ApoE), rather than HCV 
glycoproteins themselves, could be involved in this initial contact (103, 104). Also the 
low density lipoprotein receptor (LDLR) is thought to be involved in early phase of 
HCV entry (105), although this finding remains somehow controversial because 
HCV-LDLR interaction seems to involve a non-productive entry pathway that can 
potentially lead to viral particle degradation (106). HCV cell entry requires also others 
major essential cellular factors, receptors or co-receptors, like human cluster of 
differentiation 81 (CD81) (107), claudin 1 (CLDN1) (108) and occludin (OCLN) (109). 
SRB1 interacts with HCV glycoprotein E2 and lipoproteins, suggesting that it could 
be the first entry factor that interacts with the virion after initial cell attachment, 
through its lipid transfer activity, it could modify the lipid composition of the lipoprotein 
moiety of the virion, exposing the CD81 binding site on E2 glycoprotein (110). 
However, it was described that reduced dependency on SRB1 of hypervariable 
region 1 (HVR1), a part of E2 glycoprotein, in deleted mutant viruses could unmask 
the CD81 binding site of E2 glycoprotein (111, 112). Independently of these 
observations, HCV virions seem to interact with CD81 after SRB1 binding. CD81 
belongs to the family of tetraspanins and is ubiquitously expressed, except in red 
blood cells and platelets, being definitely a key player in the HCV life cycle (113). The 
CD81 actively promotes infection upon HCV binding by triggering signaling cascades 
that are important for virus entry (114). Furthermore, CD81 is highly dynamic at the 
cell surface and is enriched in membrane areas that form stable platforms, which are 
in permanent exchange with the rest of the membrane, and the balance of these 
dynamic exchanges in the cell membrane are essential to the process of HCV entry 
(99, 115, 116). The CLDN1, another essential entry factor has also been shown to 
interact with CD81 to form a co-receptor complex involved in HCV entry events (115, 
117, 118) and CD81- CLDN1 association appears to be regulated by multiple 
State of Art 
!
19 
!
signaling pathways (99). Furthermore, the viral particle might also potentially interact 
with CLDN1 (119). Additionally to CLDN1, another tight junction protein (OCLN) is 
also an essential HCV entry factor (109), that seems to play a role at the late entry 
step (120, 121), although the precise role of this protein in the HCV life cycle remains 
unclear. Recently, the cholesterol transporter Niemann-Pick C1-like 1 (NPC1L1) was 
identified as an additional HCV entry factor when was related to the high cholesterol 
presence in the HCV particles and transferrin receptor 1 as also been described to 
be involved in HCV entry, however the precise roles of them remain to be clarified 
(122). 
 Finally, HCV particle is internalized by clathrin-mediated endocytosis and 
fusion takes place in early endosomes. 
 
 
Figure 1.4. HCV entry. The HCV particle initiates its life cycle by binding to 
glycosaminoglycans (GAGs) and SRB1. Then the virus follows a complex multistep 
process, involving several specific cellular entry factors, such as SRB1, CD81, 
CLDN1 and OCLN, epidermal growth factor receptor (EGFR), transferrin receptor 
(TfR) and NPC1L1, as well as signaling proteins. After binding to several 
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components of the host cell, HCV virion is internalized by clathrin-mediated 
endocytosis and fusion takes place in early endosomes (99). 
 
 
1.13.2 - Translation and Replication 
 After infection of a cell, the positive-strand RNA genome of HCV directly 
serves as the template for translation in the cytosol (123). The 5` UTR region 
contains an internal ribosomal entry site (IRES), which initiates translation of the HCV 
genome into a single polyprotein (123). Viral and host encoded proteases process 
the viral polyprotein into the 10 mature proteins, 3 structural proteins (core, E1, E2) 
and 7 non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (124). 
Signal peptidase and signal peptide peptidase mediate cleavage of the core, E1 and 
E2 proteins, and the p7/NS2 junction (99). NS3 mediates cleavage of NS4A from 
itself and NS4B, after which NS4A associates with the N-terminus of NS3 resulting in 
a NS3/4A protease complex (99). This complex can then cleave at the NS4B/5A and 
NS5A/5B junctions, whereas the cleavage between NS2 and NS3 is mediated by the 
NS2 cysteine protease whose function is strongly enhanced by the N-terminal one-
third of NS3 (99). After translation, the HCV proteins are associated with membranes 
resultant from the endoplasmic reticulum (ER) (Figure 1.5). Replicon machinery, 
constituted by viral proteins, NS3/4A, NS4B, NS5A and NS5B, replicates the positive 
sense RNA genome through a negative strand intermediate (125). Furthermore, the 
viral RNA-dependent RNA polymerase (NS5B protein) is the key enzyme of RNA 
synthesis (99). Nascent RNA genomes are translated to produce new viral proteins, 
which could work as new or additional RNA templates for further RNA replication and 
are progressively assembled to form infectious virions (99). Moreover, microRNA 122 
(miR-122), a liver-specific microRNA that is highly expressed, acts in an unusual 
manner to stimulate accumulation of HCV RN$E\LQWHUDFWLQJZLWKWKHƍ875UHJLRQ
of the viral genome (126-128).  
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Figure 1.5. HCV replication and assembly. Upon cleavage of the polyprotein, HCV 
non-structural proteins form the replication complex in association with cellular 
factors lead to the formation of membranous web where replication takes place. After 
cleavage of its C-terminus, the core protein is loaded against low-density lipoproteins 
(LDs). The junction between core-loaded LDs and the replication-complex-rich ER 
membranes is the site of virion assembly. Newly replicated viral genomes are 
transferred to the assembly sites via NS3/4A or NS5A proteins, and NS2 protein and 
p7 protein connect replication complexes and core proteins to the glycoproteins. The 
next steps in HCV virion morphogenesis are tightly associated to the metabolism of 
very-low density lipoproteins (VLDL) assembly. However, the details of the 
intersection between HCV assembly and VLDL biogenesis remain unclear. It has 
been demonstrated that HCV particle contains ApoE and neutral lipids, but how 
these components are acquired during HCV morphogenesis remains poorly 
understood. This figure represents a hypothetical model (99). 
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1.13.3 - Assembly and Release 
 Currently, all structural and non-structural HCV proteins, alone or in 
complexes between some of them were demonstrated to be involved in the virion 
assembly process, when they interact within host cells, in pathways that occur in the 
cytosol involving lipid droplets, LDs, VLDL, apolipoproteins and receptors, for 
instance (Figure 1.5). One peculiar feature of HCV particle assembly when compared 
with other members of the Flaviviridae family is the implication of the viral non-
structural proteins in this process (99). A major component of the viral particle is the 
core protein, which interacts with the genomic RNA to form the nucleocapsid (84, 
89). After synthesis on ER membranes and cleavage by the signal peptide peptidase, 
the core protein homodimerizes and is transferred to the cytosolic LDs (129, 130). 
The envelope glycoprotein complex is also a major component of the viral particle 
and it was described that the NS2 protein interacts with envelope glycoproteins (E1 
and E2) and the p7 protein and that these interactions are essential for the migration 
of the glycoproteins heterodimer at the viral particle assembly site (131). The C-
terminal domain III of NS5A protein also involved in the viral particle assembly is 
essential for NS5A interaction with the LD-bound core protein (132), an essential 
step in HCV assembly. Moreover, NS3/4A, NS4B and NS5B proteins have also been 
described as implicated in virus assembly (133, 134). On the late stage of assembly, 
the maturation and release of HCV particles was shown to be associated with the 
VLDL pathway (133, 135). Furthermore, apolipoproteins such as apolipoprotein B 
(ApoB) can also be found in association with HCV particles; however the functional 
importance of ApoB for assembly and infectivity is controversial (136). After 
assembly and budding in the ER, HCV particles are released from cells by transit 
through the secretory pathway (137). 
 
1.14 - Epidemiology 
 HCV infections are a major global health burden and a leading cause of death 
and morbidity (138). Moreover, persistent HCV infection is associated with the 
development of liver cirrhosis, liver failure, HCC and death (139). HCV is now the 
most common cause of death in HIV positive patients on highly active antiretroviral 
therapy (140). While the incidence rate of HCV infection is apparently decreasing in 
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the developed world, however deaths from liver disease secondary to HCV infection 
will continue to increase over the next 20 years (141). Furthermore, HCV routes of 
transmission are strongly linked to the HCV high prevalence globally and is also 
related to the high genetic diversity of the virus Recently, an estimate of the disease 
burden showed an increase in seroprevalence of 2,8% in the last 15 years, equating 
to >185 million infections worldwide (142). As described above, HCV exhibits high 
genetic diversity, comprising 7 genotypes and 67 subtypes. Subtypes 1a, 1b, 2a, and 
3a, considered epidemic subtypes, are widely distributed across the world and are 
associated with a large proportion of HCV infections in high income countries (143). 
This occurred, probably due to the rapid spread of the virus before HCV discovery, 
when NANBH was associated with infected blood, blood products (72, 75) or by 
injecting drug users (144),for instance. Moreover, other HCV genotypes are 
considered endemic strains, as they are comparatively rare and have circulated for a 
long period of time in more restricted regions, such as genotype 1 and 2 endemic 
strains primarily in West Africa, genotype 3 in South Asia, genotype 4 in Central 
Africa and the Middle East, genotype 5 in Southern Africa and genotype 6 in South 
East Asia (143, 145-147). Relatively to genotype 7, few infections have been 
described in Canada and in Central Africa (148, 149). 
 A recent study involving global distribution and prevalence of HCV genotypes 
was reported (143). Considering HCV genotype prevalence published data between 
1989 and 2013 combined with overall HCV prevalence estimates from the Global 
Burden of Disease (GBD) project was accessed; 1,217 studies were included in the 
analysis, representing 117 countries and 90% of the global population (143). 
Moreover, HCV genotype 1 was shown to be the most prevalent worldwide (83.4 
million cases, 46.2% of all HCV cases), genotype 3 being the next most prevalent 
globally (54.3 million, 30.1% of all HCV cases); genotypes 2, 4, and 6 responsible for 
a total 22.8% of all cases and genotype 5 comprising the remaining <1% (Figure 1.6) 
(143). 
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Figure 1.6. HCV prevalence in countries by the majority genotype found across all 
associated studies (143). 
 
 Currently, there are just a few of isolates identified for genotype 7, the reason 
for this genotype to be not included in the described study (143). Furthermore, 
relative prevalence of each HCV genotype by GBD region and across all virus 
samples by country could be observed in figure Figure 1.7. and 1.8, respectively. 
Additionally, in Figure 1.8 considering Portugal (4 studies, Table 1 (143)) is illustrated 
that genotype 1 shown a relative prevalence between 50-75%, genotype 2 0.1-10%, 
genotype 3 25-50%, genotype 4 10-25%, genotype 5 0.1-10% and genotype 6 < 
0.1% (143). 
 
 
Figure 1.7. Relative prevalence of each HCV genotype by GBD region. The size of 
pie charts is proportional to the number of seroprevalent cases as estimated by 
Hanafiah et al. (142). 
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Figure 1.8. Relative prevalence of each genotype across all virus samples by 
country. Panel A: genotypes 1±3 (143). 
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Figure 1.8. (Continued). Relative prevalence of each genotype across all virus 
samples by country. Panel B: genotypes 4±6 (143). 
 
 Another study with the objective to characterize the natural history of HCV in 
Portugal, including current clinical practice, annual consumption of health resources 
associated with treatment and follow-up of patients in the different progression 
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stages of the disease, using the literature review of publications between 1989 and 
2013, was recently described (150). Here, it was estimated that the lower limit for the 
incidence of HCV infection in Portugal is at least 1 new case/100,000 persons per 
year and that the prevalence ranges between 1-1.5% (100,000-150,000 subjects). 
Furthermore, only 30% of the patients are currently diagnosed and 20% and 50% 
from the total number of deaths that occur by liver cirrhosis and HCC respectively are 
associated with HCV. Relatively to costs associated with HCV, the annual costs were 
about 71 million Euros of which approximately 83% (60 million Euros) are due to 
complications of the disease and liver transplant, with decompensated liver cirrhosis 
and HCC stages presenting the highest annual costs, 11,000 Euros and 17,000 
Euros/patient, respectively. 
 
1.15 - Transmission 
 The main route for HCV transmission is blood-borne including blood products 
or contaminated blood transfusions, needle sting in health workers, needle or syringe 
sharing among members of intravenous drug users (IDUs), prisoners, migrants, 
immigrants or refugees (151-156). Other risk factors are high-risk sexual behaviors, 
tattooing, shaving in a contaminated barber, reused and unsterilized dental and 
surgical instruments, and inaccurately prepared laboratory equipments (153, 157). 
 
1.16 - Diagnosis 
 Diagnosis of HCV infection is based on the presence of anti-HCV antibodies 
using enzyme immunoassay (EIA), microparticle EIA and chemiluminescence 
immunoassay. The first EIAs that were developed soon after HCV discovery 
presented low sensitivity and evolved promptly for more sensitive and specific 
assays. Currently, the detection of anti-HCV antibodies against various HCV epitopes 
is based on the use of the third-generation EIAs in plasma or serum (158). These 
assays detect antibodies to recombinant antigens from structural core protein and 
non-structural NS3, NS4 and NS5 proteins. Moreover, the specificity and sensitivity 
of the third-generation immunoassays in patients with chronic liver disease were 
found to be >98 and >97%, respectively (159, 160). However in these cases the 
diagnosis is also accompanied by molecular biological tools, such as conventional 
PCR or real-time PCR assays as they can detect minute amounts of HCV RNA and 
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accurately quantify HCV RNA levels (158, 161, 162). Furthermore, the early 
detection of HCV in infected patients leads to decrease the number of HCV-related 
HCC patients. Recently biomarkers were described for this earlier detection (163). 
Circulating microRNAs are deregulated in liver fibrosis and HCC and most recently, 
serum microRNAs as potential biomarkers for early diagnosis of HCV-related HCC 
were described (164). 
 
1.17 - Therapy 
 The primary goal of HCV treatment is to cure the infection. Following the 
European Association for the Study of the Liver (EASL) guidelines (165) until 2011, 
the approved treatment for chronic hepatitis C was the combination of pegylated 
interferon (PegIFN)-Į DQG ULEDYLULQ IRU  RU  ZHHNV (162). With this regimen, 
patients infected with HCV genotype 1 had sustained virological response (SVR) 
(defined as undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after 
treatment completion) rates of approximately 40% in North America and 50% in 
Western Europe. Higher SVR rates were achieved in patients infected with HCV 
genotypes 2, 3, 5, and 6 and intermediate SVR rates were achieved in those with 
HCV genotype 4 (166). In 2011, two first-wave, first-generation direct-acting antivirals 
(DAAs) drugs, telaprevir and boceprevir, were licensed for use in treatment against 
HCV genotype 1 infection. Both are protease inhibitors that target the HCV NS3-4A 
serine protease and must be administrated in combination with PegIFN-Į DQG
ribavirin. However, in HCV genotype 1 treatment-naïve patients, this triple therapy 
regimen achieved higher SVR rates (65% to 75%) than PegIFN-ĮDQGULEDYLULQGXDO
therapy (167, 168). In 2014, three new HCV DAAs have been licensed for use as 
part of combination therapies for HCV infection (165). Sofosbuvir (pangenotypic 
nucleotide analogue inhibitor of HCV RNA-dependent RNA polymerase), simeprevir 
(second-wave and first-generation NS3-4A protease inhibitor active against 
genotypes 1 and 4), and daclatasvir (pangenotypic NS5A inhibitor). Each of these 
three DAAs can be used as a component of a triple combination regimen with 
PegIFN-ĮDQd ribavirin, yielding SVR rates of 60±100% according to the DAA used, 
the HCV genotype, the presence of detectable pre-existing amino acid substitutions 
conferring resistance to the DAA used and the severity of liver disease (165). Similar 
2015 guidelines for HCV infection treatment were recommended in the USA (169), 
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Canada (170), and Portugal (Direcção-Geral da Saúde, Norma nº 011/2012 de 
16/12/2012 actualizada a 30/04/2015). 
 
1.18 - Cell Culture Systems 
1.18.1 - Cell Line Cultures, Cells Clones and Transfections 
 HCV primarily infects hepatocytes in the liver culminating in serious and 
progressive liver disease, as described above. However, some reports suggest that 
also non-hepatic reservoirs exist, including the lymphatic system, gut, and the brain 
(171, 172). The human hepatoma cell line (Huh)-7 seems to be the most permissive 
cell line for efficient RNA replication in vitro, as well as Huh-7 clonal derivatives (173). 
Initially, some studies using HCV replicons demonstrated that these have the 
capacity to infect the Huh-7 cells at a high level and efficiently, but this was 
dependent on cell density (174, 175) or cell passage number (176). Then, new 
studies using interferon (IFN)-Į or a selective HCV inhibitor lead to new highly 
permissive Huh-7 cell derivatives, such as Huh-7.5 (177), and Huh-7-Lunet (178) 
among others (179, 180). However, some data that resulted from these studies were 
not concordant relatively to the permissiveness of individual Huh-7 clonal derivatives 
and the reason for this was described to be strongly related to the cell host factors 
that influence HCV replication (177, 179). In 2003, for the first time was reported that 
HCV is able to replicate in human non-liver cells as well as in murine hepatoma cells 
(181). Moreover, several studies also described other HCV-permissive cells in 
human non-liver origin, human liver-derived cells, and non-human cells (182-188). 
However, RNA replication is in general lower in these cells, particularly in transient 
replication assays, compared to Huh-7-derived cell clones. It is important to note that 
in all of the described systems, for HCV replication manipulated genomic HCV strains 
or cell cultures were addressed. 
 
1.18.2 - Primary Cells and Patient Isolates 
 Primary human hepatocytes (PHH) provide the closest in vitro model for the 
natural host cell of HCV. Although, PHH are of limited availability and are provided 
from high donor variability influencing their use in HCV research. In addition, as 
primary cells they rapid lose their differentiation status which also complicates tissue 
culture experiments. Independently of these characteristic, several groups reported 
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infection of cultured PHH using sera from HCV-infected patients and CD81- and LDL 
receptor- dependent entry of serum-derived particles or inhibition of HCV replication 
by interferon was also demonstrated (189-194). However, in general low-level of 
HCV replication and reproducibility was observed. Indeed, recently, a study which is 
based on ex vivo human adult liver slices demonstrated a productive infection using 
human primary isolates of HCV genotype 1b as well as HCV isolate JFH1 and 
genotype 1 JFH1 chimeric genomes (195). This new experimental model system 
allowed the detection of high viral titers (~105 focus forming units ml-1) and validation 
of antiviral drugs too. Indeed, the development of more physiologically relevant 
infection systems is needed to provide the understanding of host±pathogen 
interactions in the liver. 
 
1.19 - Animal Models 
 There is no established, small animal model that can be used to study the 
entire viral life cycle of HCV infection and associated immunity and pathogenesis. 
Chimpanzees are the only specie that is naturally susceptible to HCV infection; the 
other primates do not appear to be susceptible to HCV infection. Chimpanzees can 
be used to completely study HCV infection as they can be infected with isolates of 1-
6 HCV genotypes and express innate and adaptive immune responses similar to 
those observed in infected humans (196, 197). While, experimentation in these large 
primates has yielded valuable insights, ethical considerations, limited availability, 
genetic heterogeneity, and cost, limit their utility. Considering all of these reasons the 
search for more controllable small animal models with numerous experimental 
approaches have been perfomed to review parts of the virus life cycle and/or aspects 
of viral pathogenesis (198). 
 In Figure 1.9 is shown an overview of described animal models used for HCV 
infection research, and their application in drug and vaccine development studies 
(198). 
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Figure 1.9. Proposed animal models in HCV research (198). Specific characteristics 
on utility and applications are indicated for each model. For all small animal models 
some areas of research are not currently feasible, which are LQGLFDWHG DV ³QRW
UHOHYDQW´ aTested by intrahepatic transfection with RNA transcripts from full-length 
HCV clones. bActivates a cellular reporter permitting bioluminescence imaging. 
cChimpanzees are not necessarily good models of chronic liver disease and HCV-
associated HCC. 
 
 Following the information provided in Figure 1.9 and all reviewed information 
by Jens Bukh in 2012 (198), Chimpanzees currently remain the only model available 
for HCV research including studies of infection and disease progression as well as 
for prophylactic and therapeutic vaccines. Moreover, these animals are also 
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important in microRNA studies as shown in a study referring the antagonist of miR-
122 (199). Certainly, the creation of mice with human hematopoietic and liver cells 
allowed researchers to reproduce HCV induced liver fibrosis in mice (200). This is 
one of the limitations of chimpanzees use for studies of HCV infection as they are not 
good models of chronic liver disease and HCV-associated HCC (198). 
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2.1 - Study Hypothesis 
 During an investigation addressing the Flaviviridae family in the search for 
VLJQLILFDQW QDWXUDO YLUXV¶V UHVHUYRLUV RI DQLPDO GLVHDVHVZHKDYH WHVWHGERG\ IOXLGV
and liver homogenates samples from domestic and wild European rabbit (O. 
cuniculus) and hare (L. europaeus) for Bovine Virus Diarrhea Virus (BVDV) antigen 
detection using a commercial blocking Enzyme-Linked Immunosorbent Assay 
(ELISA) (SerelisaTM BVD p80 Ag Mono Indirect, Symbiotics, Lyon - France) and all 
tested positive. However, when we tested serum and body fluid samples of those 
animals in the study using an antibody ELISA BVD p80 Ab Mono Blocking detection 
kit) that detects specific antibodies to a protein common to all strains of bovine viral 
diarrhea/mucosal disease (BVD/MD) and border disease (BD) virus (p80/125 non-
structural protein) they all tested negative. Efforts to detect significant Pestivirus 
proteins were unsuccessful. These observations led us to hypothesize that potential 
protein cross reactivity within members of the Flaviviridae family could explain the 
results in the preliminary work described and thus, this study was initiated. 
 
2.2 - Aims of the Study 
 In general, this work aimed to contribute in the knowledge of the role that 
European rabbit (O. cuniculus) and European hare (L. europaeus) may present as 
natural reservoirs or precursors of viruses that have a significant impact in diseases 
of animals and humans. 
 In order to reach this aim, samples from Portuguese populations of European 
rabbits (domestic and wild) and hare were processed following four proposed 
objectives: 
1. Detection of HCV specific regions by PCR and RT-PCR, using specific 
primers and sequencing. 
2. Identification and characterization of specific HCV proteins. 
3. Test the biological activities of the identified and characterized proteins in 
cell cultures. 
4. Data and phylogenetic analysis. 
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The Replication of Synthetic Fragments Homolog to HCV and to the O. 
cuniculus Genome in MDBK Cell Culture: Preliminary Results 
 
Eliane Silva1,2, Gertrude Thompson1,2 
 
1Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), D. Clínicas Veterinárias, 
Universidade do Porto, Porto, Portugal. 2Centro de Investigação em Biodiversidade e 
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Abstract 
 Our previous findings demonstrating that endogenous HCV homolog 
fragments present in the European rabbit (O. cuniculus) and European hare (L. 
europaeus) genomes can replicate in Madin-Darby bovine kidney (MDBK) epithelial 
cell, as well as that Hepatitis C-like viruses are produced in the same cell line upon 
its inoculation with European rabbit and European hare DNA, led us to  investigate if 
synthetic fragments with total homology between core, E2 and NS4B HCV proteins 
and the European rabbit genome have the ability to internalize and replicate in naïve 
MDBK cell line. The efficient internalization and replication of the selected tested 
samples could be demonstrated by virus titers detection using the quantitative real-
time RT-PCR analysis. 
 
Text 
 Unmodified or modified HCV genomic RNA belonging to different HCV 
genotypes have been synthesized, cloned and then transfected into different cell 
lines, such as hepatoma cell line (Hep) or Hep3B cells, resulting in the production of 
infectious viral particles or pseudoparticles (1, 2, 3). It was reported that unmodified 
genomic RNA derived from the HCV-2a JFH-1 strain produced infectious virions after 
transfection into Huh-7 hepatoma cells (1) and that modified synthetic RNA derived 
from a prototype HCV-1a H77 strain containing five adaptive mutations also shows 
an efficient replication in Huh-7 cells after transfection (2, 3). Moreover, a study on 
computational reconstruction of a representative synthetic HCV-1a (bole1a) 
pseudoparticle that robustly infect Hep3B cells was described (4), as it was also 
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demonstrated that the fully synthetic HCV genome contains representative epitopes 
and envelope genes that assemble properly and mediate entry into target cells. 
 Following our previous description on the capacity that endogenous HCV 
homolog fragments present in the European rabbit and European hare genomes, can 
naturally replicate in MDBK cell line (5) and that Hepatitis C-like viruses are 
produced in MDBK cell line upon its natural inoculation with European rabbit and 
European hare DNA (6), we investigated the capacity of some samples of 
synthesized fragments showing total homology between core, E2 and NS4B HCV 
proteins and the O. cuniculus genome, to passively internalize and replicate in the 
naïve MDBK cell line. Samples of synthetic fragments with total homology between 
core, E2 and NS4B HCV proteins and the O. cuniculus genome (Table 1) were 
inoculated into MDBK cell line according to procedures previously described (5). The 
cell culture medium of T25 cell culture flasks with MDBK cells (80% in confluence) 
was discarded and cells were inoculated with the synthesized samples (one sample 
per flask) and incubated at 37ºC and 5% CO2 for 4h. After this incubation period cell 
PRQROD\HU¶VZHUHZDVKHG WZLFHZLWK;SKRVSKDWHEXIIHUHGVDOLQH 3%6, and the 
new cell culture medium replaced and flasks were maintained at 37ºC and 5% CO2 
for 7 days. Subsequentially, four cell passages were performed. Uninoculated MDBK 
cells were maintained and included as negative controls in all procedures. The 
supernatants from passage 4 (P4) were used for total RNA extractions using the 
4,$DPS 9LUDO 51$ .LW 4LDJHQ +LOGHQ *HUPDQ\ IROORZLQJ WKH PDQXIDFWXUHU¶V
instructions and HCV RNA titers determined (in duplicate) by quantitative real-time 
RT-PCR analysis (qRT-PCR), HCV Real-TM Quant kit (Sacace Biotechnologies Srl, 
&RPR ,WDO\DFFRUGLQJ WR WKHPDQXIDFWXUHU LQVWUXFWLRQV LQD6WHS2QH5HDO-Time 
PCR System (Applied Biosystems, Foster, California). Virus RNA titers of ~3-5 log 
RNA copies mlí1 were detected in the tested samples (Table 2) demonstrating that 
the inoculated samples of synthetic fragments could passively infect and replicate in 
MDBK cells. Uninoculated MDBK cells (negative controls) were also tested by qRT-
PCR and no positive signal was detected. However, further studies that include these 
and other synthetic fragments as well as other methodologies are to be performed to 
further confirm these findings. Furthermore, the related host-MDBK cell line factors 
should also be investigated. Our preliminary results indicate that research in the 
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fields of HCV pathogenesis, new diagnostic tools, new antiviral targets or vaccine 
production could be further improved applying these strategies. 
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Tables 
 
Table 1. Synthetic fragments with total homology between core, E2 and NS4B HCV 
proteins and the O. cuniculus genome. 
HCV protein Synthetic fragments 
Core 186 5` - ATGTACCCCATGAGGTCGGC - 3` 
Core 134 5` - CCAAGAGGGACGGGAACCTC - 3` 
E2 5` - GCTGTCATTACAGTTAAGGGCA - 3` 
NS4B 5` - CCCACTGACAAAGTTCCACAT - 3` 
 
 
 
 
Table 2. HCV RNA titers evaluated by qRT-PCR of inoculated MDBK cells (P4) with 
synthetic fragments with total homology between HCV and the O. cuniculus genome. 
Synthetic fragments 
homologous to HCV 
HCV RNA titer (log copies 
ml-1) 
Core protein 186 ~ 5 
Core protein134 ~ 3 
Envelope ~ 3 
NS4B ~ 3 
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Abstract 
 Hepatitis C virus is a leading cause of chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma worldwide. We recently described that endogenous HCV 
homolog fragments can replicate in Madin-Darby bovine kidney epithelial cell line and 
bovine testis primary cells. Here, we show that both bovine cell cultures can also 
sustain HCV infection and replication after inoculation with patients infected sera, 
HCV uncharacterized (HCVuc), -1a and -2c genotypes using molecular biology, 
immunofluorescence and immunogold electron microscopy methods.  
 
Text 
 Hepatitis C virus (HCV) is positive-sense RNA enveloped virus of the 
Flaviviridae family and it is a leading cause of chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma worldwide (1). A detailed understanding of the virus life 
cycle, the development of new antivirals or a vaccine is urgent. HCV infects and 
replicates in liver hepatocytes of infected patients, and there was a breakthrough 
when Wakita et al. (2) described a HCV clone capable of replicating in Huh 7 cells. 
However, these cell culture systems among others like Vero cells and mosquito cells 
were not reliable when used in antiviral or molecular HCV studies (3-6). We recently 
described that endogenous HCV homolog fragments can efficiently replicate in naïve 
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bovine cell cultures, Madin-Darby bovine kidney (MDBK) epithelial cell line and 
bovine testis (BT) primary cells (7), respectively, and this could be a step forward in 
HCV research or antivirals and vaccine development. 
 HCV cell entry requires essential receptors or coreceptors like human cluster 
of differentiation 81 (CD81) (8), scavenger receptor class B type I (SR-BI) (9), claudin 
1 (CLDN1) (10) and occludin (OCLN) (11). In a recent study it was described that 
CD81 is expressed in several bovine tissues including kidney and liver (12). 
Expression of CLDN1 in bovine kidneys suggesting distinct characteristics in the tight 
junctions (TJ) (13) as well as a sequence of the bovine SR-BI HDL-receptor with a 
close identity to human sequences (14) have been also reported. OCLN, identified 
and detected in high concentration in TJ of MDBK and chick intestinal epithelial cells 
(15, 16) was also described. OCLN is an essential indicative for HCV infection of 
naturally permissive cells (11) and recently it was reported that the human OCLN is a 
HCV entry factor required for infection of mouse cells (11). Moreover, low density 
fractions from serum of patients infected with HCV established the physical 
association within lipo-viro-particle of apolipoproteins (B, CI, CII, CIII), HCV RNA and 
HQYHORSH JO\FRSURWHLQ¶V ( DQG ( (17). Also, NS3 to NS5B proteins establish 
membrane bound replication complexes that catalyze RNA replication and NS5B 
protein codes RNA-dependent RNA polymerase which serves to replicate the HCV-
RNA genome (18-20). 
 To evaluate HCV infectivity, MDBK and BT cell cultures inoculated with HCV-
1a, -2c and HCVuc infectivity titers were determined. The HCV-1a and -2c genotypes 
serum samples were obtained from HCV-infected patients, irreversibly anonymized 
at the Santo António General Hospital, Porto, Portugal; the used protocol was 
approved by the Ethics Committee of the Instituto de Ciências Biomédicas de Abel 
Salazar (ICBAS), University of Porto, Porto, Portugal (CETI; Projeto Nº 086/2014); 
and HCVuc is a HCV positive control, included in a kit INNO-LIATM HCV score 
(Innogenetics, Ghent, Belgium). MDBK and BT cells were maintained as previously 
described (7). RNA extractions from harvested cell cultures (supernatants and cells) 
from all inoculated samples, at the defined time points, were subjected to three 
freeze/thaw cycles at -80 º C/room temperatures were performed using the QIAamp 
Viral RNA Kit (Qiagen, Hilden, Germany) following the manufacturer instructions with 
VRPHPRGLILFDWLRQV%ULHIO\51$IURPFHOOO\VDWHVȝOZLWKȝORILQWHUQDOFRQWURO
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(provided in HCV Real-TM Quant kit) were extracted and RNAs were eluted with 50 
ȝORIEXIIHUAVE. HCV RNA titers from extracted RNA were measured at the defined 
time points by a 5` UTR quantitative Real Time-PCR (qPCR), HCV Real-TM Quant 
kit (Sacace Biotechnologies Srl, Como, Italy) according to the manufacturer 
LQVWUXFWLRQV LQ D 6WHS2QH 5HDO-Time PCR System (Applied Biosystems, Foster, 
California). 
 For BT and MDBK cell cultures infected with HCVuc stock (1.24E+03 IU/ml) 
for 336h and 1008h, respectively, HCV RNA titers (mean of two determinations) 
ranged from 103 to 105 and from 103 to 106 IU/ml, respectively. Moreover, HCV RNA 
titers (mean of two determinations) ranged from 103 to 104 IU/ml and 104 IU/ml were 
determined in MDBK cells inoculated with genotypes -1a (3.76E+03 IU/ml) and -2c 
(1.18E+04 IU/ml) stocks for 336h, respectively. To further characterize the different 
YLUXV¶V LQIHFWLYLW\ SDWWHUQV NLQHWLF H[SHULPHQWV LQ0'%. DQG%7 FHOO FXOWXUHVZHUH
performed. After inoculation of MDBK and BT cell cultures with HCVuc stock, a ~3 
log increase in HCV RNA titers to a peak titer of 106 IU/ml was observed (Fig. 1A, 
1B). However, when MDBK cell cultures were inoculated with HCV-1a stock and 
HCV-2c stock a ~1 log increase in HCV RNA titers raised to peak titers of 104 and 
105 IU/ml, respectively, was observed (Fig. 1C). Interesting aspects of the use of 
MDBK and BT culture systems are that even starting with low inoculums 
concentration, the virus concentration for the studied samples was continuously high 
with little variation for incubation period and a virus livelihood is also observed. 
Lázaro et al. (21) were able to demonstrated that human fetal hepatocyte cultures 
can be infected by patient serum of various HCV genotypes, HCV-1a included, but 
only about 80% of the tested samples were able to infect these cell cultures. A study 
using MDBK and others cell cultures infected with HCV-3a were recently described 
(22) but the authors were not able to demonstrated HCV-3a infection in MDBK cells. 
However, ours results demonstrate the infectivity of different HCV genotypes in 
MDBK cells and we previously demonstrated that homolog HCV fragments with high 
homologies to different HCV genotypes, HCV-3a included, also replicate in these 
cells.  
 To investigate the infectivity and replication of inoculated HCV-positive 
samples in MDBK and BT cell cultures IFA and IEM assays were performed using 
mouse monoclonal antibodies (MAbs) anti-HCV NS3, anti-HCV NS4A and anti-HCV 
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NS5 as previously described (7). MDBK cell cultures were infected with HCVuc stock 
for 336h and 1008h, respectively. For both inoculated cell cultures, cells were 
harvested at 336h post infection (p.i) and tested by IFA and IEM using mouse MAbs 
anti-HCV NS3, anti-HCV NS4A and anti-HCV NS5 and specific immunostaining for 
the three selected antibodies could be demonstrated (Fig. 2A, 2B). Negative controls 
(uninoculated MDBK and BT cells) that have been treated with the selected MAbs 
were included and no reaction was detected (Fig. 2A, 2B). Immunogold particles 
were detected in different cell organelles such as nucleous, mitochondria and 
cytoplasm (Fig. 2B) consistent with others reports previously described for HCV 
replication in cell cultures (23, 24). Immunogold particles were also detected in TJ 
when MAbs anti-HCV NS5 (Fig. 2B) were used suggesting high relation with the HCV 
cell entry and OCLN that is highly concentrated in these intercellular junctions. MDBK 
cells were also infected with HCV-1a and HCV-2c stocks for 336h. Harvested cells 
using MAbs anti-HCV NS3 (16 and 48h) and anti-HCV NS5 (16, 48 and 96h) were 
tested by IFA and specific immunostaining for the two selected MAbs could be 
observed (Fig. 3A, 3B). Negative controls (uninoculated MDBK cells) treated with the 
selected MAbs were included and no reaction was detected (Fig. 3A, 3B). 
 The presence of the essential HCV cell entry factors in bovine tissues (e.g. 
kidney, liver, MDBK cells), as described above, and the obtained results by IFA, IEM 
and qPCR for the studied samples successfully demonstrate the permissibility of the 
used bovine cell cultures to HCV. Among this, we suggest the bovine cell cultures, in 
particular MDBK cell line, as a new efficient in vitro model for studies of HCV 
pathogenesis, for the development of effective antivirals and vaccines as tools for 
therapeutics and prevention of this disease. 
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Figures 
 
Figure 1. Comparative kinetics studies of intergenotypic viruses of HCVuc, HCV-1a 
and HCV-2c. MDBK and BT cells were infected with the respective stock virus for 
several weeks and HCV RNA titers were detected in harvested supernatants and 
cells by qPCR. a, HCVuc, BT infected cells at 168 and 336h post infection. b, 
HCVuc, MDBK infected cells at 168 and 336h p. i. c, HCV-1a and -2c, MDBK 
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infected cells at 6, 48,72, 96, 144 and 336h p. i. HCV RNA titers were measured 
under the detection limit of the used test. 
 
 
Figure 2. Detection of HCV proteins by IFA and IEM in BT and MDBK cell cultures 
infected with HCVuc. BT and MDBK cell cultures infected with serum from HCV-
infected patient, HCVuc, harvested at 336h p. i. a, Both cell cultures tested by IFA 
using mouse MAbs anti-HCV NS3, anti-HCV NS4A and anti-HCV NS5. Scale bars: 
ȝP%7± NS3 and NS5 NC, MDBK ± 161&DQG+&9XFDQGȝPRWKHUVE
MDBK cell cultures tested by IEM using the same MAbs as in IFA. The immunogold 
particles were detected in mitochondria (mt), cytoplasm (cy), nucleous (nc) and tight 
junctions (tj). Arrows indicate the presence of gold particles. The immunogold 
particles were 10 nm in diameter. Scale bars: 200 nm. Negative controls (NC) for 
each cell culture treated with the selected MAbs were also performed. No 
fluorescence or immunogold particles were detected. 
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Figure 3. Detection of HCV proteins by IFA in MDBK cell cultures infected with HCV-
1a and HCV-2c. a, IFA using MAbs anti-HCV NS3 (16 and 48h) and anti-HCV NS5 
(16, 48 and 96h) from harvest cells infected with HCV-D6FDOHEDUVDQGȝP
(only HCV-1a NS3-16h). b, IFA using the same MAbs and at the same time points 
from harvest cells infected with HCV-F6FDOHEDUVȝP1HJDWLYHFRQWUROV 1&
treated with the selected MAbs were also performed and no fluorescence was 
detected. 
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 This dissertation contains one international patent application, two published 
papers in international journals and two preliminary studies that will be improved for 
publication in international journals. A detailed discussion and conclusions of each 
related experimental work is presented in previous chapters of this thesis, relatively 
to each study. A general discussion and conclusions of the studies carried out are 
presented in this chapter as well as some future perspectives. 
 
5.1 - General Discussion 
 Hepatitis C is a human contagious liver disease that results from the  infection 
with the HCV, a positive RNA virus, which is characterized by a +ssRNA genome that 
belongs to the Flaviviridae family (1). To date, the HCV origin remains unclear and 
the HCV life cycle and pathogenesis are not enlightened processes due to the 
absence of HCV efficient cell cultures systems or animals models. However recently, 
several studies reporting homologs of HCV detected in small wild animals, rodents 
and bats, and in domesticated animals, dogs and horses were described (2-4). The 
discovery of these HCV-like viruses in animals may contribute to the understanding 
of the HCV origins in humans, and for instance for studies related to the virus 
pathogenesis or immune responses. 
 Partially, our investigation, aimed to search for significant natural viruses 
reservoirs associated to animal or human diseases as explained in the investigation 
hypothesis of this work as described above, led us to understand the role that the 
European rabbit (O. cuniculus) and European hare (L. europaeus) could play as 
natural reservoirs of Flaviviridae and more specifically precursors of HCV-like viruses 
in this dissertation. Moreover, molecular biology methods such as PCR, sequencing, 
proteomic, cell cultures and immune screenings methods, as well as bioinformatics 
tools were procedures aimed for the accomplishment of this proposal. 
 Therefore, the first chapter of this dissertation includes the state of the art on 
cell foreign DNA integration, endogenous viral elements, positive RNA viruses, the 
European rabbit and European hare, rabbits as animal model and the HCV history 
focusing in the taxonomy, virus life cycle, epidemiology, routes of transmission, 
diagnosis, therapy, cell cultures systems approaches and proposed animal models. 
 The second chapter focuses in the study hypothesis that led to this 
dissertation approaches as well as for the aims of the study. 
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 The third chapter describes the detection and characterization of HCV 
homologous fragments present in the European rabbit and European hare genome. 
Preliminary work on the detection of endogenous HCV homolog fragments in the 
European rabbit and European hare that showed the capacity to infect and 
autonomously replicate in permissive bovine cell cultures, MDBK epithelial cell line 
and BT cells respectively was performed. Additionally, total DNA that was extracted 
from rabbit and hare liver samples and selected synthesized nucleotides or peptides 
homologous to HCV, were demonstrated to also have the ability to infect and 
autonomously replicate in MDBK cell cultures. A human wild type HCV-1a isolate 
was also shown to passively infect and replicate in MDBK cells. This preliminary work 
led to the application of an international patent (5), as the criterions for a patent 
application and publication must obligatory anticipate other publications related to the 
study work. The application for a patent was submitted and published, providing the 
methods and tools that can contribute for the identification of novel antivirals, vaccine 
production, new diagnostic tools as well as a better understanding of the HCV life 
cycle, its origin and diversity, the pathogenesis mechanisms of the virus using the 
tested bovine cells as cell models. Unfortunately the patent application could not 
enter the national, European or international phase classification, due to the 
comments by the written opinion of the international searching authorities (5). 
 Following the patent application, a manuscript describing that endogenous 
HCV homolog fragments in European rabbit and hare genomes replicate in cell 
cultures was published (6). Specifically, it was described that endogenous 
KRPRORJRXV'1$ IUDJPHQWV FRGLQJ IRU+&9 FRUH HQYHORSH JO\FRSURWHLQ¶V(DQG
E2, protease NS2-3, serine protease NS3, NS4A, NS5A and NS5B specific proteins 
present in the animal genomes were able to internalize and replicate in MDBK and 
BT cell cultures, although with no virus-like particles detection or visualization in the 
analyzed samples (6). As discussed in this publication and above in this thesis, 
endogenous flaviviruses have previously been reported in the genomes of 
mosquitoes (7, 8) without determined complete putative genomic structures and 
EVEs have also been identified and demonstrated in animal genomes (9). 
Additionally, to understand if the described endogenous homologous HCV fragments 
in the rabbit and hare would be able to produce entire viral particles with infectious 
proprieties in the MDBK cell line became a requisite, and it was proven that they 
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were able, when we demonstrated that HCV-like viruses are produced in MDBK 
cells, after their inoculation with rabbit and hare DNA extracted from animals livers 
homogenates samples (10). Moreover, the phylogenetic analysis revealed the 
presence of viruses genetically similar to HCV, designated rabbit (RHCV) and hare 
(HHCV) HCV-like viruses, and that RHCV was closely related to the HCV-1a/HCV-1b 
genotypes and HHCV was more closely related to the HCV-1b genotype (10). As 
previously discussed in this thesis, we proved that the rabbit and the hare have small 
EVEs homologous to all HCV genetic specific regions that, when exposed to the 
MDBK cells (potential suitable biological substrate) are able to internalize the cells 
and initiate its own replication using the host cell machinery to produce entire HCV-
like particles. The previously described functional pathways of ssRNA+ viruses 
genomes such as, the virion (genomic) RNA is the same sense as mRNA and 
therefore can function as mRNA that can be immediately translated by host cell 
machinery upon infection, working the genomic RNA as template for viral RNA 
replication (11, 12) strongly elucidated us in the understanding and in the viability of 
all this process to occur.  
 Finally, a slight improve was achieved for the study on the replication of HCV 
homologous synthetic fragments in MDBK cells and is described. We investigated if 
synthetic fragments with total homology between core, E2 and NS4B HCV proteins 
and the European rabbit genome have the capacity to internalize and replicate in 
naïve MDBK cell line. This hypothesis was proven by the detection of virus RNA 
titers of ~3-5 log RNA copies mlí1 were detected in tested samples by qRT-PCR 
analysis. However, more research including these and others synthetic fragments as 
well as others methodologies must be performed to further confirm this data and the 
related host-MDBK cell line factors should also be investigated. We will improve this 
study to accomplish its publication in an international journal. The overall findings 
prompt us to state that all of the aimed objectives proposed for this dissertation were 
accomplished. 
 The fourth chapter of this thesis, the last related for the performed 
experimental work, and that was not included in the aims of this study but was 
essential to the patent submission, is related to the hypothesis that bovine cell 
cultures, MDBK cell line and BT primary cells, could be used as cell models for the 
wild type HCV replication using patients infected sera, HCV uncharacterized 
(HCVuc), HCV-1a and HCV-2c genotypes. For BT and MDBK cell cultures infected 
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with HCVuc, HCV RNA titers ranging from 103-105 and from 103-106 IU/ml 
respectively were detected. Moreover, HCV RNA titers ranging from 103-104 IU/ml 
and 104 IU/ml were determined in MDBK cells inoculated with genotypes -1a and -2c 
respectively. HCV specific immunostaining was also detected in both cell cultures 
inoculated with the tested samples by immunofluorescence and/or immunogold 
electron microscopy methods. Immunogold particles were detected in different cell 
organelles such as nucleous, mitochondria, cytoplasm and tight junctions accordingly 
with reports previously described for HCV replication in cell cultures (13, 14). 
 The overall acquired data and the above described presence of essential cell 
receptors or coreceptors for HCV entry in bovine tissues led us to suggest the bovine 
cell cultures as cell models for HCV genotypes infection and replication, specially the 
MDBK cells as they are a cell line culture. The MDBK cells could be a new efficient in 
vitro model for studies of HCV pathogenesis, HCV life cycle, development of new 
effective antivirals and probably a vaccine production. 
 
5.2 - Conclusions 
 At the beginning of the present thesis we proposed to study the genomic 
integration of HCV homologous fragments in the European rabbit and European 
hare, and the possibility for its detection and characterization. We successfully 
detected HCV homologous fragments in the European rabbit and European hare and 
were able to further characterize them.  
 Additionally, we were able to suggest bovine cell cultures as cell culture 
models for wild type HCV viruses and we showed that MDBK cell line could be a 
model for wild type HCV genotypes infection and replication. Therefore, the main 
conclusions of this thesis are: 
x Endogenous HCV homolog fragments coding for such as HCV core, envelope 
JO\FRSURWHLQ¶V(DQG(SURWHDVH16-3, serine protease NS3, NS4A, NS5A 
and NS5B specific proteins were demonstrated in European rabbit and hare 
genomes. 
x The endogenous HCV homolog fragments are able to replicate in bovine cell 
cultures, MDBK cell line and BT primary cell cultures. 
x Hepatitis C-like viruses are produced in MDBK cell cultures after inoculation of 
rabbit and hare genomic DNA and named RHCV and HHCV respectively. 
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x The produced RHCV is closely related to the HCV-1a/HCV-1b genotypes and 
HHCV is more closely related to the HCV-1b genotype. 
x To date the produced RHCV and HHCV are the most HCV-like viruses 
associated to animals that are more closely related to HCV. 
x The suggestive replication of synthetic fragments homologs to HCV was 
demonstrated in MDBK cells. 
x Bovine cell cultures, particularly the MDBK cell line could be a considered a 
cell model for HCV replication. 
x The data presented in this dissertation could contribute to understand the HCV 
origin and for a better understanding of the virus life cycle and pathogenesis, 
as well as contribute to the discovery of new antivirals and perhaps a vaccine 
production. 
 
5.3 - Future Perspectives 
x Improve the study of the synthetic fragments in MDBK cell cultures. Also 
evaluating their functional mechanisms in the perspective and approach for 
new antivirals or new antiviral targets. 
x Improve the study on the mechanisms of wild type HCV strains replication in 
MDBK cell cultures. 
x Explore the MDBK cell line in the context of the detection and understanding 
the receptors or coreceptors present in the MDBK cells that make them 
permissive for these viruses. 
x Explore the HCV life cycle in MDBK cells. 
x Initiate animal experimental pathogenesis studies using the rabbit as a model: 
inoculation of rabbits with produced HCV-like viruses, RHCV and HHCV 
respectively as well as with HCV wild type  
x Further explore the rabbit as an animal model for research on HCV. 
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